Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Basal Bolus Clear all
Completed Not applicable Interventional

Efficacy of Structured Insulin Order

NCT01130558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Diabetes Management
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2010 · Synced Sep 23, 2026, 7:31 PM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional

Controlled Insulin Delivery: Combining Technology With Treatment

NCT01484457
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed-loop session
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Feasibility of Using the CGM During TOC From in Persons With T2D Using Insulin

NCT04533945
View directory record Official record
Conditions
Diabetes, Type 2 Diabetes
Interventions
FreeStyle Libre
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 23, 2026, 7:31 PM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

NCT00978627
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 23, 2026, 7:31 PM EDT
Terminated Phase 4 Interventional

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
h-Patch
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes

NCT01409239
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient
Interventions
Intravenous insulin, Subcutaneous Insulin
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Not applicable Interventional Results available

Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

NCT01945138
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes Mellitus
Interventions
Closed Loop Insulin
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Continuous Femoral Nerve Blocks: Relative Effects of Basal Infusion and Bolus Doses on Sensory and Motor Function

NCT01144559
View directory record Official record
Conditions
Nerve Block
Interventions
Continuous Infusion, Bolus Administered
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2010 · Synced Sep 23, 2026, 7:31 PM EDT
Terminated Phase 3 Interventional Results available

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

NCT01136746
View directory record Official record
Conditions
Hyperglycemia
Interventions
Human regular insulin, Insulin lispro, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)

NCT04880850
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
52
States / cities
Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 23, 2026, 7:31 PM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Not applicable Interventional

Exercise Activity-Based Bolus Decisions in Type 1 Diabetes

NCT03394352
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Activity on Board, Usual Diabetes Care
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

Continuous Subcutaneous Infusion of Pramlintide and Insulin

NCT00291772
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
13 Years to 22 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes

NCT01087567
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensive insulin, Routine Care
Drug
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 23, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

App-Based Certified Diabetes Education Therapy (AB-CDE)

NCT07282639
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
DailyDose
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 2 Interventional

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

NCT01662921
View directory record Official record
Conditions
Diabetes During Pregnancy
Interventions
NPH, Insulin LISPRO, Insulin glulisine
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

NCT00591227
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 23, 2026, 7:31 PM EDT